文献速递神经免疫

血清神经丝轻链与那他珠单抗治疗复发缓解型多发性硬化进展的关联

Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
PubMed 文献 · Neurology · 2021-09-09

该研究纳入89例接受那他珠单抗治疗的复发缓解型多发性硬化患者,随访中位5.2年,每年进行临床和MRI评估,并在5个时间点检测血清NfL。结果显示NfL在治疗3个月后显著下降,1年时达基线近50%,但进展者与非进展者的NfL纵向变化无差异,基线及1年时NfL不能预测末次随访时的进展。结论提示NfL无法捕捉或预测与急性局灶性炎症活动无关的疾病进展。

要点

  • 那他珠单抗治疗后3个月血清NfL显著下降,1年时降至基线近50%。
  • 进展者与非进展者的血清NfL纵向变化无显著差异。
  • 基线及治疗1年时NfL水平不能预测末次随访时的疾病进展。

核心结论

  • 在那他珠单抗治疗的复发缓解型多发性硬化患者中,血清NfL无法捕捉或预测主要独立于急性局灶性炎症活动之外的疾病进展。
  • 可能需要额外的生物标志物来监测这类患者的疾病进展。

研究设计与样本

  • 研究为前瞻性观察性队列研究,始于2006年荷兰阿姆斯特丹VU大学医学中心。
  • 纳入89例接受那他珠单抗治疗的复发缓解型多发性硬化患者,年龄≥18岁,随访至少3年。
  • 每年进行临床和MRI评估,并在5个时间点检测血清NfL:基线(那他珠单抗起始日)、3个月、1年、2年及末次随访。
  • 采用一般线性回归模型比较进展者与非进展者之间NfL的纵向变化。

主要发现

  • 中位随访时间5.2年(IQR 4.3-6.7,范围3.0-11.0),那他珠单抗起始时平均年龄36.9岁(SD 8.5),中位疾病病程7.4年(IQR 3.8-12.1)。
  • 第1年至末次随访间,28/89(31.5%)患者出现确认的EDSS进展。
  • EDSS+复合终点数据 available 于73/89例患者,其中35/73(47.9%)出现确认的EDSS+进展。
  • 那他珠单抗起始后3个月NfL水平显著下降,1年时达到最低点,接近基线水平的50%。
  • 进展者与非进展者之间NfL的纵向变化无差异;基线及治疗1年时NfL水平不能预测末次随访时的进展。

临床怎么用

  • 对于接受那他珠单抗治疗的复发缓解型多发性硬化患者,不应仅依赖血清NfL来监测或预测疾病进展。
  • 需结合临床和MRI评估,并考虑开发额外生物标志物以监测独立于急性炎症的进展。

局限性

  • 研究为单中心观察性队列,样本量89例,结果需外部验证。
  • EDSS+终点数据仅 available 于73/89例患者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To investigate the potential of serum neurofilament light (NfL) to reflect or predict progression mostly independent of acute inflammatory disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab. METHODS: Patients were selected from a prospective observational cohort study initiated in 2006 at the VU University Medical Center Amsterdam, the Netherlands, including patients with RRMS treated with natalizumab. Selection criteria included an age of 18 years or older and a minimum follow-up of 3 years from natalizumab initiation. Clinical and MRI assessments were performed on a yearly basis, and serum NfL was measured at 5 time points during the follow-up, including on the day of natalizumab initiation (baseline), 3 months, 1 year, and 2 years after natalizumab initiation, and on last follow-up visit. Using general linear regression models, we compared the longitudinal dynamics of NfL between patients with and without confirmed Expanded Disability Status Scale (EDSS) progression between year 1 visit and last follow-up, and between individuals with and without EDSS+ progression, a composite endpoint including the EDSS, 9-hole peg test, and timed 25-foot walk. RESULTS: Eighty-nine natalizumab-treated patients with RRMS were included. Median follow-up time was 5.2 years (interquartile range [IQR] 4.3-6.7, range 3.0-11.0) after natalizumab initiation, mean age at time of natalizumab initiation was 36.9 years (SD 8.5), and median disease duration was 7.4 years (IQR 3.8-12.1). Between year 1 and the last follow-up, 28/89 (31.5%) individuals showed confirmed EDSS progression. Data for the EDSS+ endpoint was available for 73 out of the 89 patients and 35/73 (47.9%) showed confirmed EDSS+ progression. We observed a significant reduction in NfL levels 3 months after natalizumab initiation, which reached its nadir of close to 50% of baseline levels 1 year after treatment initiation. We found no difference in the longitudinal dynamics of NfL in progressors vs nonprogressors. NfL levels at baseline and 1 year after natalizumab initiation did not predict progression at last follow-up. CONCLUSION: In our cohort of natalizumab-treated patients with RRMS, NfL fails to capture or predict progression that occurs largely independently of clinical or radiologic signs of acute focal inflammatory disease activity. Additional biomarkers may thus be needed to monitor progression in these patients. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that serum NfL levels are not associated with disease progression in natalizumab-treated patients with RRMS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Bridel C, Leurs CE, van Lierop ZYGJ, et al. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. Neurology. 2021. PMID: 34504023. doi:10.1212/WNL.0000000000012752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。